WBO:CVAC (Germany)  
CureVac NV logo

CureVac NV

€ 7.66 (-3.93%) Sep 23
P/E:
At Loss
P/B:
2.13
Market Cap:
€ 1.43B ($ 1.38B)
Enterprise V:
€ 888.25M ($ 860.68M)
Volume:
-
Avg Vol (2M):
890.00
Also Trade In:
Volume:
-
Market Cap €:
1.43B
Market Cap $:
1.38B
PE Ratio:
At Loss
Avg Vol (2-Month):
890.00
Enterprise Value €:
888.25M
Enterprise Value $:
860.68M
PB Ratio:
2.13
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 14.35
Equity-to-Asset 0.67
Debt-to-Equity 0.07
Debt-to-EBITDA -0.2
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.85
Distress
Grey
Safe
Beneish M-Score 1.11
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 5.17
9-Day RSI 12.15
14-Day RSI 18.44
6-1 Month Momentum % -38.13
12-1 Month Momentum % -77.04

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.45
Quick Ratio 3.39
Cash Ratio 2.95
Days Inventory 84.46
Days Sales Outstanding 40.6
Days Payable 102.6

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.1

Financials (Next Earnings Date:2022-11-18 Est.)

WBO:CVAC's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 115.084
EPS (TTM) (€) -1.16
Beta 0
Volatility % 69.26
14-Day RSI 18.44
14-Day ATR (€) 0.342426
20-Day SMA (€) 9.50465
12-1 Month Momentum % -77.04
52-Week Range (€) 7.66 - 49.595
Shares Outstanding (Mil) 187.47

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

CureVac NV Filings

Document Form Filing Date
No Filing Data

CureVac NV Analysis

Share your research